Nationwide use of REBOA in adolescent trauma patients: An analysis of the AAST AORTA registry.


Journal

Injury
ISSN: 1879-0267
Titre abrégé: Injury
Pays: Netherlands
ID NLM: 0226040

Informations de publication

Date de publication:
Nov 2020
Historique:
received: 15 07 2020
revised: 03 08 2020
accepted: 07 08 2020
pubmed: 17 8 2020
medline: 22 6 2021
entrez: 17 8 2020
Statut: ppublish

Résumé

Trauma is the leading cause of death for children and adolescents. Resuscitative endovascular balloon occlusion of the aorta (REBOA) is a minimally invasive method of hemorrhage control used primarily in adults. We aimed to characterize REBOA use in pediatric patients. The American Association for the Surgery of Trauma (AAST) Aortic Occlusion for Resuscitation in Trauma and Acute Care Surgery (AORTA) registry was queried for patients <18 years old undergoing REBOA placement (2013-2020). The primary outcome was mortality. Secondary outcomes included injury severity score (ISS), additional interventions, and complications. Eleven patients with a median age of 17 years old had REBOA placed, with a survival rate of 30%. Inflation of the REBOA balloon resulted in a significant increase in systolic blood pressure (SBP) (median SBP pre-REBOA 53 mmHg vs. post-REBOA 110 mmHg, p=0.0007). Patients were severely injured with a median ISS of 29 (interquartile range 16-42). There were no access-site complications. All three surviving patients had a discharge Glasgow Coma Scale of 15. REBOA is used in patients <18 years old, but all reported patients in this registry were adolescents. No REBOA-related complications were reported. Identifying pediatric patients who may benefit from REBOA and modifying currently existing technology for this group of patients is an area of ongoing research.

Sections du résumé

BACKGROUND BACKGROUND
Trauma is the leading cause of death for children and adolescents. Resuscitative endovascular balloon occlusion of the aorta (REBOA) is a minimally invasive method of hemorrhage control used primarily in adults. We aimed to characterize REBOA use in pediatric patients.
METHODS METHODS
The American Association for the Surgery of Trauma (AAST) Aortic Occlusion for Resuscitation in Trauma and Acute Care Surgery (AORTA) registry was queried for patients <18 years old undergoing REBOA placement (2013-2020). The primary outcome was mortality. Secondary outcomes included injury severity score (ISS), additional interventions, and complications.
RESULTS RESULTS
Eleven patients with a median age of 17 years old had REBOA placed, with a survival rate of 30%. Inflation of the REBOA balloon resulted in a significant increase in systolic blood pressure (SBP) (median SBP pre-REBOA 53 mmHg vs. post-REBOA 110 mmHg, p=0.0007). Patients were severely injured with a median ISS of 29 (interquartile range 16-42). There were no access-site complications. All three surviving patients had a discharge Glasgow Coma Scale of 15.
CONCLUSION CONCLUSIONS
REBOA is used in patients <18 years old, but all reported patients in this registry were adolescents. No REBOA-related complications were reported. Identifying pediatric patients who may benefit from REBOA and modifying currently existing technology for this group of patients is an area of ongoing research.

Identifiants

pubmed: 32798039
pii: S0020-1383(20)30681-1
doi: 10.1016/j.injury.2020.08.009
pmc: PMC7609470
mid: NIHMS1619692
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2512-2516

Subventions

Organisme : NCATS NIH HHS
ID : UL1 TR001860
Pays : United States

Informations de copyright

Copyright © 2020. Published by Elsevier Ltd.

Auteurs

Christina M Theodorou (CM)

University of California Davis Medical Center, Department of Surgery. Sacramento, CA, USA. Electronic address: ctheodorou@ucdavis.edu.

Megan Brenner (M)

University of California Riverside, Department of Surgery. Riverside, CA, USA.

Jonathan J Morrison (JJ)

University of Maryland, Department of Surgery. Baltimore, MD, USA.

Thomas M Scalea (TM)

University of Maryland, Department of Surgery. Baltimore, MD, USA.

Laura J Moore (LJ)

University of Texas Health Sciences Center Houston, Department of Surgery. Houston, TX, USA.

Jeremy Cannon (J)

University of Pennsylvania, Department of Surgery. Philadelphia, PA, USA.

Mark Seamon (M)

University of Pennsylvania, Department of Surgery. Philadelphia, PA, USA.

Joseph J DuBose (JJ)

University of Maryland, Department of Surgery. Baltimore, MD, USA.

Joseph M Galante (JM)

University of California Davis Medical Center, Department of Surgery. Sacramento, CA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH